Next Article in Journal
Safety, Tolerability, and Immunogenicity of Interferons
Next Article in Special Issue
Health Economics of Antibiotics
Previous Article in Journal
The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
Previous Article in Special Issue
Lessons Learned from Surveillance of Antimicrobial Susceptibilities of Pseudomonas aeruginosa at a Large Academic Medical Center
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2010, 3(4), 1139-1161; doi:10.3390/ph3041139

Lysostaphin: A Staphylococcal Bacteriolysin with Potential Clinical Applications

Departamento de Microbiologia Geral, Instituto de Microbiologia Prof. Paulo de Góes, CCS, Bloco I, UFRJ, 21941-590, Rio de Janeiro, RJ, Brazil
*
Author to whom correspondence should be addressed.
Received: 24 March 2010 / Revised: 8 April 2010 / Accepted: 14 April 2010 / Published: 19 April 2010
(This article belongs to the Special Issue Antibiotics)
View Full-Text   |   Download PDF [439 KB, uploaded 19 April 2010]   |  

Abstract

Lysostaphin is an antimicrobial agent belonging to a major class of antimicrobial peptides and proteins known as the bacteriocins. Bacteriocins are bacterial antimicrobial peptides which generally exhibit bactericidal activity against other bacteria. Bacteriocin production is a self-protection mechanism that helps the microorganisms to survive in their natural habitats. Bacteriocins are currently distributed into three main classes. Staphylococcins are bacteriocins produced by staphylococci, which are Gram-positive bacteria of medical and veterinary importance. Lysostaphin is the only class III staphylococcin described so far. It exhibits a high degree of antistaphylococcal bacteriolytic activity, being inactive against bacteria of all other genera. Infections caused by staphylococci continue to be a problem worldwide not only in healthcare environments but also in the community, requiring effective measures for controlling their spread. Since lysostaphin kills human and animal staphylococcal pathogens, it has potential biotechnological applications in the treatment of staphylococcal infections. In vitro and in vivo studies performed with lysostaphin have shown that this staphylococcin has potential to be used, solely or in combination with other antibacterial agents, to prevent or treat bacterial staphylococcal infectious diseases.
Keywords: lysostaphin; staphylococci; antimicrobial peptides; bacteriocins; staphylococcins lysostaphin; staphylococci; antimicrobial peptides; bacteriocins; staphylococcins
Figures

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Bastos, M.C.F.; Coutinho, B.G.; Coelho, M.L.V. Lysostaphin: A Staphylococcal Bacteriolysin with Potential Clinical Applications. Pharmaceuticals 2010, 3, 1139-1161.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top